TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer

Human Pathology

Volumn 38, Issue 4, 2007, Pages 614-620

  Ogino, Shuji ^a,b,c   Kawasaki, Takako ^b   Ogawa, Akiyo ^b   Kirkner, Gregory J ^a   Loda, Massimo ^a,b,c   Fuchs, Charles S ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CIMP; Colon cancer; MSI; RUNX3; TGF

Indexed keywords

CALCIUM CHANNEL; CELLULAR RETINOL BINDING PROTEIN 1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PROTEIN MLH1; PROTEIN P16; SOMATOMEDIN B; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; COLORECTAL CANCER; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN ANALYSIS; STRATIFICATION; TUMOR DIFFERENTIATION;

COHORT STUDIES; COLORECTAL NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 33947121581     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.10.005     Document Type: Article

References (35)

1. Grady W.M. Genomic instability and colon cancer. Cancer Metastasis Rev 23 (2004) 11-27
2. Parsons R., Myeroff L.L., Liu B., et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55 (1995) 5548-5550
3. Markowitz S., Wang J., Myeroff L., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268 (1995) 1336-1338
4. Watanabe T., Wu T.T., Catalano P.J., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344 (2001) 1196-1206
5. Goel A., Arnold C.N., Tassone P., et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 112 (2004) 754-759
6. Kim T.Y., Lee H.J., Hwang K.S., et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 84 (2004) 479-484
7. Ku J.L., Kang S.B., Shin Y.K., et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23 (2004) 6736-6742
8. Ito Y. Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells 4 (1999) 685-696
9. Wei D., Gong W., Oh S.C., et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65 (2005) 4809-4816
10. Suzuki M., Shigematsu H., Shames D.S., et al. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 93 (2005) 1029-1037
11. Calonge M.J., and Massague J. Smad4/DPC4 silencing and hyperactive ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem 274 (1999) 33637-33643
12. Bulus N.M., Sheng H.M., Sizemore N., et al. Ras-mediated suppression of TGFbetaRII expression in intestinal epithelial cells involves Raf-independent signaling. Neoplasia 2 (2000) 357-364
13. Jiang B., Zhang J.S., Du J., et al. Growth inhibitory signalling by TGFbeta is blocked in Ras-transformed intestinal epithelial cells at a post-receptor locus. Cell Signal 15 (2003) 699-708
14. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 4 (2004) 988-993
15. Jass J.R. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2 (2005) 398-405
16. Toyota M., Ohe-Toyota M., Ahuja N., et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A 97 (2000) 710-715
17. Toyota M., Ahuja N., Ohe-Toyota M., et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96 (1999) 8681-8686
18. Samowitz W., Albertsen H., Herrick J., et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129 (2005) 837-845
19. Ogino S., Cantor M., Kawasaki T., et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55 (2006) 1000-1006
20. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38 (2006) 787-793
21. Eads C.A., Danenberg K.D., Kawakami K., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28 (2000) E32
22. Ogino S., Kawasaki T., Brahmandam M., et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8 (2006) 209-217
23. Colditz G.A., and Hankinson S.E. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5 (2005) 388-396
24. Wei E.K., Giovannucci E., Fuchs C.S., et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97 (2005) 1688-1694
25. Ogino S., Kawasaki T., Kirkner G.J., et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 8 (2006) 582-588
26. Ogino S., Brahmandam M., Cantor M., et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19 (2006) 59-68
27. Ogino S., Kawasaki T., Brahmandam M., et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7 (2005) 413-421
28. Bacher J.W., Flanagan L.A., Smalley R.L., et al. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers 20 (2004) 237-250
29. Ogino S., Brahmandam M., Kawasaki T., et al. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 8 (2006) 458-464
30. Ogino S., Kawasaki T., Kirkner G.J., et al. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 20 (2007) 15-22
31. Samowitz W.S., Curtin K., Neuhausen S., et al. Prognostic implications of BAX and TGFBRII mutations in colon cancers with microsatellite instability. Genes Chromosomes Cancer 35 (2002) 368-371
32. Yan Z., Deng X., and Friedman E. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. J Biol Chem 276 (2001) 1555-1563
33. Iacopetta B.J., Welch J., Soong R., et al. Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: relationship to clinicopathological features and genetic alterations. J Pathol 184 (1998) 390-395
34. Jung B., Smith E.J., Doctolero R.T., et al. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int J Cancer 118 (2006) 2509-2513
35. Fernandez-Peralta A.M., Nejda N., Oliart S., et al. Significance of mutations in TGFBR2 and BAX in neoplastic progression and patient outcome in sporadic colorectal tumors with high-frequency microsatellite instability. Cancer Genet Cytogenet 157 (2005) 18-24